FDA Approves Zurnai (nalmefene hydrochloride) Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose

FDA approves Zurnai (nalmefene hydrochloride) auto-injector for emergency treatment of opioid overdose, indicated for adults and patients aged 12+ with respiratory/CNS depression. Zurnai, containing 1.5 mg nalmefene per dose, is designed for immediate administration in opioid-present settings, not a substitute for emergency care. Contraindicated in hypersensitive patients. Purdue Pharma aims to provide Zurnai at no profit, addressing the opioid crisis.